Published in Oncotarget on December 13, 2016
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
mTOR signaling in growth control and disease. Cell (2012) 29.21
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc (2007) 12.39
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther (2002) 3.55
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res (2010) 3.20
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J (2001) 2.55
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
Phosphoinositide 3-kinases in cell migration. Biol Cell (2009) 1.95
Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front Biosci (2007) 1.91
Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet (2004) 1.85
Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates gamma-H2AX. Mol Cell Biol (2010) 1.73
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev (2010) 1.72
Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol (1998) 1.68
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene (2012) 1.63
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol (2013) 1.59
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res (2015) 1.53
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res (2009) 1.45
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci (2008) 1.43
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol (2011) 1.34
Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett (2012) 1.32
ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol (2004) 1.29
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol (2015) 1.28
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol (2012) 1.27
Targeting PI3K in Cancer: Any Good News? Front Oncol (2013) 1.18
Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res (2014) 1.11
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med (2015) 1.09
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res (2012) 1.07
Cisplatin resistance and opportunities for precision medicine. Pharmacol Res (2016) 1.01
The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep (2015) 1.01
Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol (2014) 0.99
Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol (2014) 0.96
Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Expert Rev Mol Diagn (2010) 0.96
RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Oncogene (2012) 0.95
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett (2015) 0.85
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Invest New Drugs (2014) 0.84
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. Br J Cancer (2015) 0.82
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Mol Carcinog (2015) 0.81
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Curr Top Microbiol Immunol (2010) 0.80
Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway. Cell Mol Life Sci (2016) 0.79
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. Cancer Res (2016) 0.78